Next article Search Articles Instructions for authors  Access Statistics | Citation Manager  
CASE REPORT  

 Article Access Statistics
    Viewed582    
    Printed10    
    Emailed0    
    PDF Downloaded58    
    Comments [Add]    

Recommend this journal


Click on image for details.

 Outcomes following the use of angiotensin II in patients with postoperative vasoplegic syndrome: A case series

Samuel B Konkol1, Matthew J Morrisette2, Matthew C Hulse3, Kyle B Enfield4, Andrew D Mihalek4
1 Department of Internal Medicine, University of Virginia Health, Charlottesville, VA, USA
2 Department of Pharmacy, University of Virginia Health, Charlottesville, VA, USA
3 Department of Anesthesiology and Critical Care Medicine, University of Virginia Health, Charlottesville, VA, USA
4 Department of Pulmonary and Critical Care Medicine, University of Virginia Health, Charlottesville, VA, USA

Correspondence Address:
Andrew D Mihalek
1215 Lee St. Charlottesville, VA 22903
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aca.aca_98_21

Rights and Permissions

Year : 2022  |  Volume : 25  |  Issue : 3  |  Page : 359-361

 
SEARCH
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles

  Article in PDF (758 KB)
Email article
Print Article
Add to My List
Catecholamine-resistant postoperative vasoplegic syndrome (PVS) lacks effective treatment modalities. Synthetic angiotensin II was recently approved for the treatment of vasodilatory shock; however, its use in PVS is not well described. We report outcomes in six patients receiving angiotensin II for the treatment of isolated PVS. All patients achieved their MAP goal and the majority showed improvement in lactate and background catecholamine dose; however, variables of perfusion changed discordantly. Three of six patients survived to hospital discharge.






[FULL TEXT] [PDF]*
 

 

  Sitemap | Feedback | Disclaimer | Privacy Notice | What's New  
  © Annals of Cardiac Anaesthesia | Published by Wolters Kluwer - Medknow
 Online since 5th January, 2008

 

 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 
 
 Reader Comments
 Email Alert *
  *
 * Requires registration (Free)
 
 CASE REPORT
 



Samuel B Konkol1, Matthew J Morrisette2, Matthew C Hulse3, Kyle B Enfield4, Andrew D Mihalek4
1 Department of Internal Medicine, University of Virginia Health, Charlottesville, VA, USA
2 Department of Pharmacy, University of Virginia Health, Charlottesville, VA, USA
3 Department of Anesthesiology and Critical Care Medicine, University of Virginia Health, Charlottesville, VA, USA
4 Department of Pulmonary and Critical Care Medicine, University of Virginia Health, Charlottesville, VA, USA

Correspondence Address:
Andrew D Mihalek
1215 Lee St. Charlottesville, VA 22903
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aca.aca_98_21

Rights and Permissions

Catecholamine-resistant postoperative vasoplegic syndrome (PVS) lacks effective treatment modalities. Synthetic angiotensin II was recently approved for the treatment of vasodilatory shock; however, its use in PVS is not well described. We report outcomes in six patients receiving angiotensin II for the treatment of isolated PVS. All patients achieved their MAP goal and the majority showed improvement in lactate and background catecholamine dose; however, variables of perfusion changed discordantly. Three of six patients survived to hospital discharge.






[FULL TEXT] [PDF]*


        
Print this article     Email this article  

  Sitemap | Feedback | Disclaimer | Privacy Notice | What's New  
  © Annals of Cardiac Anaesthesia | Published by Wolters Kluwer - Medknow
 Online since 5th January, 2008